Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,724 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Not applicable Interventional Results available

Early Cognitive Intervention in Delirium

NCT04740567
View directory record Official record
Conditions
Delirium, Cognitive Decline, Dementia
Interventions
Cognitive Training, Goal Management Training
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 1:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800
View directory record Official record
Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
Interventions
CD47 Antagonist ALX148, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional

We-Move With Windy: Gross Motor Development for Early Childhood

NCT07346300
View directory record Official record
Conditions
Physical Activities
Interventions
We Move with Windy
Behavioral
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Not applicable Interventional

Glucose to Goal: A Model to Support Diabetes Management in Primary Care

NCT02715934
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Glucose to Goal, Usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
4,994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 30, 2026, 1:28 AM EDT
Suspended Not applicable Interventional

Virtual Reality Treadmill Training in Individuals With Traumatic Brain Injury

NCT05721209
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
C-Mill with AR/VR Guidance, C-Mill without AR/VR Guidance, Zeno 3-Layer Walkway, Hunova
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Results available

Pectoralis Block vs Paravertebral Nerve Blocks for Breast Surgery

NCT04742309
View directory record Official record
Conditions
Breast Surgery
Interventions
Pecs-2 block (single injection), Paravertebral block (single injection)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 30, 2026, 1:28 AM EDT
Terminated Phase 1 Interventional

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798
View directory record Official record
Conditions
Lymphoma
Interventions
CC-220, Rituximab, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 1:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

NCT02983604
View directory record Official record
Conditions
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Interventions
GS-5829, Exemestane, Fulvestrant
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

iADAPT: Off Label Use of Antipsychotics in the Nursing Home

NCT01347619
View directory record Official record
Conditions
Off-label Use of Atypical Antipsychotic Drugs
Interventions
Toolkit only with Web Access to Online Version, Toolkit, Periodic Audit/Feedback, Educational Messages, Items in Arm 2 plus Academic Detailing Program
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rocky Hill, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders

NCT01784809
View directory record Official record
Conditions
HIV, Sexually Transmitted Infections
Interventions
Multimedia WORTH, Traditional WORTH, Wellness Promotion
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
CYT387
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Not applicable Interventional

Expanding Interventions for Automatically Maintained SIB

NCT06739616
View directory record Official record
Conditions
Self-Injurious Behavior, Problem Behavior, Intellectual Disability, Autism Spectrum Disorder, Restricted Behavior
Interventions
AUTOSIB across time, AUTOSIB diminished reinforcement
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
2 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Randolph, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 30, 2026, 1:28 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

NCT01134601
View directory record Official record
Conditions
Non-Metastatic Adenocarcinoma of the Rectum
Interventions
Radiation Therapy, Capecitabine, AZD6244
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630
View directory record Official record
Conditions
Obesity, Knee Osteoarthritis (OA)
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111 )
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Walnut Creek, California • Hamden, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Withdrawn Not applicable Interventional

Exercise and Nutritional Intervention for Deconditioned Older Adults

NCT01115530
View directory record Official record
Conditions
Muscle Weakness
Interventions
Resistance exercise, Protein and HMB (see below) supplement
Other · Dietary Supplement
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years to 90 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Phase 1 Interventional

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

NCT07172971
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Not listed Not applicable Interventional

Prescriptive Mobilization Versus a Pragmatic Mobilization

NCT01940744
View directory record Official record
Conditions
Mechanical Low Back Pain
Interventions
Prescriptive Mobilization, Pragmatic Mobilization
Procedure
Lead sponsor
Walsh University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Des Moines, Iowa • North Canton, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional

The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial

NCT05754632
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Knee Injuries, Quadriceps Muscle Atrophy
Interventions
Blood Flow Restriction using Delfi Personalized Tourniquet System
Device
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

A Study of RO4989991 in Patients With Allergic Rhinitis

NCT01152619
View directory record Official record
Conditions
Asthma
Interventions
Placebo, RO4989991
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
South Miami, Florida • Normal, Illinois • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 1:28 AM EDT